companies / biofidelity-com
Generated UTC · publication cutoff 2026-11-09
Insufficient cited evidence for a two-sentence summary.
verified=2026-05-17 json
| total_raised | 23,760,00023.8M | ○ |
|---|---|---|
| founded | 2018 | |
| hq | Cambridge, UK | |
| industry | unknown | |
| stage | series-a |
Aspyre Lung clinical test profiles 11 NSCLC genes from DNA and RNA in tissue or blood with next-day turnaround. Used by oncologists and pathology labs that need rapid molecular profiling for non-small-cell lung cancer. Detects mutations and gene fusions in a single workflow on samples with as little as 10% tumour content.
No cited completed company acquisition recorded.
Dated disclosures. Customer relationships and classifications are historical; ARR is separate from revenue.
No cited disclosure recorded: named customer, disclosed revenue, ARR, count, B2B / B2C, sector, go-to-market.
No cited valuation with an explicit basis is recorded.
Historical post-money / actual annual or stated TTM revenue. Same currency; economic valuation date within 90 days of revenue period end, inclusive. No FX, ARR, annualized revenue, estimates or projections. Conflicts and ambiguous ties are withheld.
No qualifying pair recorded.
| date | type | amount | lead | src |
|---|---|---|---|---|
| 2024-04-01 | series-a | 23,760,00023.8M | null | ○ |
| person | role | src |
|---|---|---|
| BALMFORTH, Barnaby William | director | CH |
| CHOUDRY, Uzma, Dr | director | CH |
| DREISMANN, Heinrich | director | CH |
| FRANKLIN, Matthew Douglas | director | CH |
| FRAYLING, Cameron Alexander | director | CH |
| FROHN, Matthew | director | CH |
| HAKES, Luke, Dr | director |
Cloudflare, Linkedin Ads, Linkedin Insight Tag, Google Analytics, Google Tag Manager, Slick, jQuery Migrate 3.4.1, DoubleClick Floodlight, HubSpot, Cloudflare Bot Management, WordPress, WordPress Block Editor
| fact | status | src |
|---|---|---|
| Series A, $23.8M | attributed | ○ |
| existence | self-reported | WEB |
| description | self-reported | WEB |
| O'LEARY, Ciaran | director | CH |